The company has expanded its portfolio to include Oncotype DX, a suite of genomic tests that analyze tumor biology to guide treatment decisions, and through strategic acquisitions and internal development, has positioned itself as a leader in precision oncology, offering comprehensive cancer screening, diagnosis, and treatment selection solutions. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.
Cyborg Score Rationale
The company raised full-year 2025 revenue guidance to between $3.22 billion and $3.235 billion, with screening revenue hitting $666 million in Q3 2025 alone. The non-GAAP gross margin remains high at 71% in Q3 2025, and the company generated $190 million in free cash flow in Q3 2025. However, the pending acquisition creates execution uncertainty.
Top Insights
Abbott agreed to acquire Exact Sciences for approximately $21 billion, with shareholders expected to receive $105 per share and the deal expected to close in Q2 2026.
The company launched three major tests in 2025: the Cologuard Plus test, the Oncodetect molecular residual disease (MRD) test, and the Cancerguard multi-cancer early detection (MCED) test.
Despite recent downsizing with a reduction of 200 employees, the company maintains a robust revenue stream of over 1 billion dollars, suggesting capacity for strategic investments in automation tools, data management systems, and scalable lab solutions.
The company has license agreements with MAYO Foundation for Medical Education and Research, Johns Hopkins University, as well as Freenome Holdings, Inc.
Named Competitors
Guardant Health — Blood-based cancer diagnostics and monitoring
Illumina — Genomic sequencing and analysis platforms
Natera — Non-invasive prenatal and cancer testing
Laboratory Corporation — Diagnostic testing and drug development services
Recent Developments
(November 2025) Abbott Laboratories agreement to acquire Exact Sciences for approximately $21 billion
(July 2025) Workforce reduction of 200 employees, including 80 in Madison